Chardan Capital Reiterates “Buy” Rating for Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. Chardan Capital’s price objective would suggest a potential upside of 40.06% from the company’s current price.

Senti Biosciences Trading Down 28.6 %

Shares of NASDAQ SNTI opened at $7.14 on Monday. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The firm’s 50-day moving average is $2.46 and its 200-day moving average is $2.66. The firm has a market capitalization of $32.77 million, a PE ratio of -0.46 and a beta of 2.69.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.